---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059009"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-05-12T11:35:31+00:00"
generated_at: "2026-05-12T11:41:28.092341+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026

## Summary
- Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).
- Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.
- Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.
- Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.
- Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation.

## SEC filing metadata
- accession: 0001104659-26-059009
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-05-12T11:35:31+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/0001104659-26-059009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059009
- JSON: https://secwatch.observer/filing/0001104659-26-059009.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059009.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026, was $10.7 million.
  - Period: the quarter ended March 31, 2026
  - Net income: Net loss for the quarter ended March 31, 2026, was $10.7 million
  - Result: reported results
  source text: Sagimet Biosciences Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/0001104659-26-059009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.